Suchergebnisse - "Le Cornet, Lucian"

PubPharm (21)

1

Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive post-remission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemia

enthalten in: Haematologica | 2024

von Jaramillo, S. | Krisam, J. | Le Cornet, L. | +17

2

Risk of hematological malignancies from CT radiation exposure in children, adolescents and young adults

enthalten in: Nature medicine | 2023

von Bosch de Basea Gomez, M. | Thierry-Chef, I. | Harbron, R. | +30

3

Protocol of the IntenSify-Trial : An open-label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab-paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate the combination's pharmacokinetics, safety, and efficacy

enthalten in: Clinical and translational science | 2023

von Hohmann, N. | Sprick, M. | Pohl, M. | +19

4

Q-HAM : a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD

enthalten in: Trials | 2023

von Jaramillo, S. | Le Cornet, L. | Kratzmann, M. | +23

5

Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD

enthalten in: Trials | 2023

von Jaramillo, S. | Le Cornet, L. | Kratzmann, M. | +23

6

Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD

enthalten in: Trials | 2023

von Jaramillo, S. | Le Cornet, L. | Kratzmann, M. | +23

7

Brain cancer after radiation exposure from CT examinations of children and young adults : results from the EPI-CT cohort study

enthalten in: The Lancet. Oncology | 2023

von Hauptmann, M. | Byrnes, G. | Cardis, E. | +26

CommentIn: Lancet Oncol. 2023 Jan;24(1):2-3. - PMID 36493794

8

Q-HAM : a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD

enthalten in: Trials | 2023

von Jaramillo Segura, S. | Le Cornet, L. | Kratzmann, M. | +23

9

Protocol of the IntenSify‐Trial : An open‐label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab‐paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate the combination's pharmacokinetics, safety, and efficacy

enthalten in: Clinical and Translational Science | 2023

von Hohmann, N. | Sprick, M. | Pohl, M. | +19

10

Author Correction : The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology

enthalten in: Nature cancer | 2022

von Tamborero, D. | Dienstmann, R. | Rachid, M. | +79

ErratumFor: Nat Cancer. 2022 Feb;3(2):251-261. - PMID 35221333